Teva Pharmaceuticals has announced that it will exclusively manufacture a generic version of the brand-name antiretroviral (ARV) medication Reyataz (atazanavir).
Reyataz is approved to be used in combination with two or more other ARVs to treat HIV. It is also included in the combination tablet Evotaz (atazanavir/cobicistat). Teva will produce Reyataz as a single pill only.
Teva now has five ARV generics in its portfolio.
The company made waves in June 2017 when the Food and Drug Administration (FDA) indicated that the agency had approved a generic version of Truvada (tenofovir disoproxil fumarate/emtricitabine) for both HIV treatment and pre-exposure prophylaxis (PrEP) and that Teva had received exclusive manufacturing rights. The approval, however, appeared more to be a component of an opening salvo in a drawn-out legal process between Teva and Gilead Sciences—which manufactures brand-name Truvada—that may take years to conclude, after which Teva would finally have the green light to produce a generic version of that tablet. The patent on Truvada as a combination tablet does not expire until 2021.
To read a press release from Teva, click here.